{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-057131","form_type":"8-K/A","ticker":null,"cik":"0001828522","company_name":"eFFECTOR Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.464589+00:00","generated_at":"2026-06-02T06:55:37.076230+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"eFFECTOR Therapeutics enters $50M ATM equity offering with H.C. Wainwright, terminates Cantor agreement","bullets":["Entered Sales Agreement with H.C. Wainwright & Co. to sell up to $50M of common stock via ATM offerings.","Agent will receive a 3.0% commission on gross proceeds from any shares sold under the agreement.","Terminated prior ATM agreement with Cantor Fitzgerald; 1,075,405 shares had been sold for $9.8M.","No obligation to sell; sales will be made on Nasdaq Capital Market at prevailing market prices."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-057131","json":"https://secwatch.observer/filing/0000950170-24-057131.json","markdown":"https://secwatch.observer/filing/0000950170-24-057131.md","text":"https://secwatch.observer/filing/0000950170-24-057131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828522/000095017024057131/0000950170-24-057131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828522/000095017024057131/eftr-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:55:37.076230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40157618c661729f4306409145feda11488d4a9a","claim":"eFFECTOR Therapeutics, Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at $9.8 million (effective 2024-05-09).","evidence_excerpt":"On May 9, 2024, the Company terminated its Controlled Equity Offering SM Sales Agreement, dated September 1, 2022, with Cantor Fitzgerald & Co. (the “Prior Sales Agreement”), pursuant to which the Company was able sell shares of common stock in “at the market offerings” as defined by Rule 415 of the Securities Act.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000095017024057131/0000950170-24-057131-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co."},{"label":"Value","value":"$9.8 million"},{"label":"Effective","value":"2024-05-09"}],"fact_type":"material_agreement"},{"claim_id":"f461820e0cff85d2d3aae507e2485308b8b7eb62","claim":"eFFECTOR Therapeutics, Inc. entered into At the Market Offering Agreement with H.C. Wainwright & Co., LLC valued at aggregate offering price of up to $50.0 million (effective 2024-05-09).","evidence_excerpt":"On May 9, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) entered into an At the Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), under which the Company may, from time to time, sell shares of the Company’s common stock having an aggregate offering price of up to $50.0 million through the Agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828522/000095017024057131/0000950170-24-057131-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Value","value":"aggregate offering price of up to $50.0 million"},{"label":"Effective","value":"2024-05-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}